In the BioHarmony Drug Report Database

"Preview" Icon

Abametapir

Xeglyze (abametapir) is a small molecule pharmaceutical. Abametapir was first approved as Xeglyze on 2020-07-24. It is used to treat pediculus in the USA. Xeglyze’s patents are valid until 2034-12-17 (FDA).

 

Trade Name

 

Xeglyze
 

Common Name

 

abametapir
 

ChEMBL ID

 

CHEMBL2205807
 

Indication

 

pediculus
 

Drug Class

 

Pediculicide, metalloproteinase inhibitor

Image (chem structure or protein)

Abametapir structure rendering